ARROWHEAD PHARMACEUTICALS, INC. Cash And Cash Equivalents At Carrying Value

Quick Answer

ARROWHEAD PHARMACEUTICALS, INC. reported Cash And Cash Equivalents At Carrying Value of $184.43 million for the year ending 2021.

  • ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +28.5% in Cash And Cash Equivalents At Carrying Value from 2020 to 2021.
  • This data is from ARROWHEAD PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on November 22, 2021.
  • XBRL data for this metric is available from 2010 to 2021 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q3 2009: $2.02 million | Q2 2010: $8.98 million | Q4 2010: $5.47 million | Q1 2011: $4.79 million | Q2 2011: $4.32 million | Q4 2011: $6.77 million | Q1 2012: $3.60 million | Q2 2012: $2.28 million | Q4 2012: $2.93 million | Q1 2013: $3.31 million | Q2 2013: $29.03 million | Q4 2013: $59.71 million | Q1 2014: $142.85 million | Q2 2014: $138.35 million | Q4 2014: $103.99 million | Q1 2015: $96.45 million | Q2 2015: $87.25 million | Q4 2015: $62.17 million | Q1 2016: $50.30 million | Q2 2016: $43.62 million | Q4 2016: $102.11 million | Q1 2017: $61.72 million | Q2 2017: $38.38 million | Q3 2017: $24.84 million | Q4 2017: $11.53 million | Q1 2018: $69.81 million | Q2 2018: $28.00 million | Q4 2018: $189.77 million | Q1 2019: $161.64 million | Q2 2019: $188.33 million | Q4 2019: $461.03 million | Q1 2020: $256.65 million | Q2 2020: $219.32 million | Q4 2020: $139.92 million | Q1 2021: $372.38 million | Q2 2021: $325.98 million | Q3 2021: $184.43 million | Q4 2021: $91.59 million | Q1 2022: $86.41 million | Q2 2022: $139.44 million.
  • Over the full 12 years of available data (2010 to 2021), ARROWHEAD PHARMACEUTICALS, INC.'s Cash And Cash Equivalents At Carrying Value has grown by 2,593.6%.
  • Historical annual values: Fiscal year 2021: $184.43 million | Fiscal year 2020: $143.58 million | Fiscal year 2019: $221.80 million | Fiscal year 2018: $30.13 million | Fiscal year 2017: $24.84 million | Fiscal year 2016: $85.37 million | Fiscal year 2015: $81.21 million | Fiscal year 2014: $132.51 million | Fiscal year 2013: $19.11 million | Fiscal year 2012: $3.38 million | Fiscal year 2011: $7.51 million | Fiscal year 2010: $6.85 million.
  • Data sourced from SEC EDGAR public filings as of August 10, 2026.

Last verified: